Company News: Page (1) of 1 - 04/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality

If approved by the FDA, esketamine nasal spray would be the first medication for treatment of patients with major depressive disorder at imminent risk for suicide (April 16, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA,Medicine,Disease,Therapy,Surgery,Medication,Science,Lifestyle,Medical,Science,Adults,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved